What CAR-T involves
CAR-T therapy collects a patient's T cells, engineers them to recognise a cancer-associated antigen, and returns them after lymphodepleting treatment. It is used in selected lymphomas, leukemias and myeloma. The process takes time and requires close coordination between the referring doctor and the cellular therapy centre.
Related: Haematology → · Dr. Sachita Baniya profile → · All conditions →
Eligibility and monitoring
Eligibility depends on the disease subtype, antigen expression, prior therapies, organ function and performance status. After infusion, patients need monitoring for fever, low blood pressure, breathlessness, confusion, seizures or speech change. Long-term follow-up includes blood counts and disease surveillance.
- Disease and antigen eligibility review
- Prior treatment and organ function assessment
- Referral and bridging therapy coordination
- CRS and neurotoxicity monitoring
- Long-term response and infection follow-up
Access
Dr. Baniya consults at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, and also practises at Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital, Kathmandu, and Advanced Care Hospital. CAR-T availability and referral pathways are discussed for the individual case.